Intravenous Vitamin C in Combination With Standard Chemotherapy for Pancreatic Cancer
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
Eligible candidates will be adults with metastatic pancreatic cancer (confirmed diagnosis
with pathology reports and measurable computed tomography (CT) or magnetic resonance imaging
(MRI)). Participants must not be receiving any other concurrent chemotherapy, or radiation
therapy. Full inclusion/exclusion criteria are available. History and physical examination,
and laboratory and imaging analyses will be done within 14 days prior to registration. The
three cohorts of subjects will receive 50, 75 or 100 grams of intravenous ascorbic acid,
three times per week for 8 weeks. Subjects will also have co-administration of the
chemotherapy medications, gemcitabine (intravenously) and erlotinib (orally). Approximately 9
to 18 participants will be enrolled in this Phase I study.
Phase:
Phase 1
Details
Lead Sponsor:
Sidney Kimmel Cancer Center at Thomas Jefferson University Thomas Jefferson University